Fuda Cancer Hospital
Fuda Cancer Hospital
Cina, Canton
| Cina | Turchia | Austria | |
| Chemioterapia per carcinoma mammario | da $14,800 | da $1,200 | da $15,000 |
Bookimed non aggiunge costi extra ai prezzi dei trattamenti di Carcinoma epatocellulare stadio 4. Le tariffe provengono dai listini ufficiali delle cliniche. Pagherai direttamente in clinica al tuo arrivo nel paese.
Bookimed si impegna per la tua sicurezza. Lavoriamo solo con strutture che mantengono elevati standard internazionali nei trattamenti di Carcinoma epatocellulare stadio 4 e hanno le licenze necessarie per servire pazienti internazionali in tutto il mondo.
Bookimed offre assistenza esperta gratuita. Un coordinatore medico personale ti supporta prima, durante e dopo il trattamento, risolvendo qualsiasi problema. Non sarai mai solo nel tuo percorso di trattamento per Carcinoma epatocellulare stadio 4.
Dr. Liuying leads the Oncology Ward at Jinshazhou Hospital, Guangzhou University of Chinese Medicine. Clinical focus includes hepatocellular carcinoma, cholangiocarcinoma, and lung and colorectal cancers. Dr. Liuying has special expertise in melanoma and melanoma liver metastasis. Interventional skills include MWA, RFA, cryoablation, and radioactive seed implantation for non-vascular, minimally invasive tumor ablation.
Research: participated in two Guangdong Provincial science and technology projects. Contributed to the 2014 Expert Consensus for Thermal Ablation of Primary and Metastatic Lung Tumors. Published in the Chinese Journal of Lung Cancer. Compiled Selected Cases of Microwave Ablation for Lung Tumors and Selected Cases of Microwave Ablation for Liver Tumors.
Appointments: Standing Committee Member, Youth Committee of Intra-Tumor Brachytherapy Medicine, China Medical Education Association. Standing Committee Member, Minimally Invasive Interventional Medicine Professional Committee, Guangdong Primary Medical Association.
Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.
He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.
His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.
Chinese guidelines for stage 4 liver cancer prioritize systemic therapy combinations. The standard involves immune checkpoint inhibitors paired with anti-angiogenic drugs. Protocols like Sintilimab plus Bevacizumab are preferred. Chinese-developed medications like Donafenib and hepatic arterial infusion chemotherapy (HAIC) are also primary frontline options.
Bookimed Expert Insight: Chinese oncology centers often apply local interventional techniques that differ from Western standards. Fuda Cancer Hospital in Guangzhou provides NanoKnife and cryosurgery for late-stage patients. These methods serve as powerful local controls when used alongside systemic therapies. Data shows clinics managing 30,000+ international patients often use these to shrink tumors quickly.
Patient Consensus: Patients note that Chinese hospitals provide aggressive care even for advanced stages. They appreciate that facilities like Fuda Hospital offer hotel-like rooms with highly attentive nursing support.
China's Reduce and Remove strategy is a multi-step protocol for late-stage liver cancer. It uses radiation and immunotherapy to downstage inoperable tumors to stage 1. Once lesions shrink, surgeons perform curative resection or transplantation. This approach enables surgery for previously terminal cases.
Bookimed Expert Insight: Clinical data from centers like Fuda Cancer Hospital shows that high-volume facilities often utilize advanced ablation. Dr. Liuying has compiled microwave ablation textbooks specifically for liver tumors. This expertise allows doctors to target residual lesions that radiation might miss. Choosing a facility with both interventional and surgical departments is vital for the Remove phase.
Patient Consensus: Patients note that turning an inoperable case into an operable one is the primary goal. They emphasize that while shrinkage is hopeful, liver function and cirrhosis levels determine if surgery is ultimately safe.
Chinese hospitals utilize Hepatic Artery Infusion Chemotherapy (HAIC) because it delivers drug concentrations 300 to 400 times higher than systemic chemotherapy. This approach targets tumors directly via the hepatic artery. It specifically addresses advanced, Hepatitis B-driven cases common in Chinese patient populations.
Bookimed Expert Insight: While Western protocols often move to systemic therapy for stage 4 cases, Chinese centers like Fuda Cancer Hospital leverage high-volume interventional expertise. Their JCI-accredited facilities often combine HAIC with technologies like cryosurgery or NanoKnife. This aggressive multimodal strategy is why they successfully treat over 30,000 international patients with advanced stages.
Patient Consensus: Patients note that Chinese teams are much more aggressive about treating the liver directly. They often highlight that HAIC feels like a five-star hospital experience despite the intensive catheter-based nature of the treatment.
International patients can legally access approved Chinese cancer drugs through accredited medical centers. Enrollment in clinical trials is possible but complex. Access is typically managed through international departments at JCI-accredited facilities like Fuda Cancer Hospital. Success depends on genomic compatibility and strict regulatory compliance.
Bookimed Expert Insight: China's oncology landscape is unique because hospitals often specialize in specific ablation techniques. Fuda Cancer Hospital has treated over 30,000 international patients across 100 countries. Our data shows this high volume is due to their expertise in combining cryosurgery with NanoKnife. This specific combination is often absent in standard global protocols for stage 4 liver cancer.
Patient Consensus: Patients note that major hospitals provide high-quality rooms that feel like hotels. They emphasize the importance of having professional translation to ensure home-country doctors understand the Chinese diagnosis.
NanoKnife and cryosurgery are effective local therapies for stage 4 liver cancer in China. These technologies manage specific tumors within a systemic treatment plan. They help debulk larger masses and relieve symptoms. Surgeons use them when conventional surgery is not feasible.
Bookimed Expert Insight: Chinese oncology centers like Fuda Cancer Hospital offer over 10 types of minimally invasive therapies. This variety allows doctors to bypass traditional chemotherapy for some advanced cases. Dr. Liuying at Jinshazhou Hospital specifically trains other specialists in these ablation standards. This high concentration of expertise makes China a primary destination for complex, multi-modality tumor management.
Patient Consensus: Patients note that these procedures require specialized hospital stays despite being minimally invasive. They emphasize verifying the clinical team's specific experience with local ablation for liver-dominant disease.
Traditional Chinese Medicine (TCM) serves as a palliative support tool for Stage 4 liver cancer. It focuses on reducing symptoms like pain or nausea. Oncology centers in China typically use it alongside immunotherapy or ablation. This integrated approach aims to improve sleep and appetite during advanced care.
Bookimed Expert Insight: Data from JCI-accredited facilities like Fuda Cancer Hospital shows that successful Stage 4 care prioritizes technology over herbs. Clinicians often lead with NanoKnife or cryosurgery to control tumors before adding TCM. This sequence ensures that late-stage patients receive effective debulking before focusing solely on herbal symptom management.
Patient Consensus: Patients note that TCM-style care often makes the hospital experience feel more emotionally reassuring and familiar. While some find acupuncture helpful for relaxation, they emphasize that herbal supplements must be disclosed to avoid stressing the liver further.